Equillium, Inc. EQ · Stock Open Equillium, Inc. in new tab
Equillium, Inc. Analysis (EQ)
Is Equillium, Inc. a good investment? Equillium, Inc. (EQ) is currently trading at 1.90 USD. Market analysts have a consensus price target of 8.56 USD. This suggests a potential upside from current levels.
Earnings Schedule: Equillium, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.23.
Investor FAQ
Does Equillium, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Equillium, Inc.?
Equillium, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.09.
Company Profile
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Community Discussion